✨ The funding will be used for research and development and to increase manufacturing capacity to meet demand in Europe and the US.
🔬 Nyxoah focuses on developing innovative solutions to treat Obstructive Sleep Apnea (OSA) with its Genio system.
💡 The loan is part of the European Commission’s InvestEU program and follows a recent successful equity offering by Nyxoah.
Introduction:
Nyxoah SA, a medical technology company based in Mont-Saint-Guibert, Belgium, has secured a €37.5 million loan facility agreement with the European Investment Bank (EIB) through the European Commission’s InvestEU program. The funding will be used for research and development, as well as to scale-up manufacturing capacity to meet demand in Europe and the U.S.
- Nyxoah has signed a €37.5 million loan facility agreement with the EIB to support its research and development efforts and scale up manufacturing capacity.
- The loan is divided into three tranches and is backed by the European Commission’s InvestEU program.
- The company focuses on the development and commercialization of innovative solutions for Obstructive Sleep Apnea (OSA), with its flagship product being the Genio system.
- The Genio system consists of a neurostimulator, activation chip, charging unit, and adhesive patches, which are implanted under the chin to stimulate the hypoglossal nerve.
- EIB Vice-President Robert de Groot emphasizes the importance of supporting innovative companies in the life sciences and med tech industry, and Nyxoah’s contribution to patient care.
Conclusion:
Nyxoah’s €37.5 million loan from the EIB will provide support for the company’s research and development efforts and help increase its manufacturing capacity. The funding will enable Nyxoah to meet the growing demand for its innovative solutions for treating Obstructive Sleep Apnea, ultimately benefiting patients worldwide. This investment highlights Belgium’s position as a leader in life sciences and med tech innovation and demonstrates the EIB’s commitment to fostering growth in the industry.
